Get the Stockscreener App
70.80
0.06%
-0.04
After Hours:
70.80
Avidity Biosciences Inc stock is traded at $70.80, with a volume of 2.39M.
It is down -0.06% in the last 24 hours and up +47.10% over the past month.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
See More
Previous Close:
$70.84
Open:
$70.8
24h Volume:
2.39M
Relative Volume:
0.48
Market Cap:
$10.33B
Revenue:
$10.73M
Net Income/Loss:
$-455.74M
P/E Ratio:
-19.90
EPS:
-3.5569
Net Cash Flow:
$-502.70M
1W Performance:
+1.37%
1M Performance:
+47.10%
6M Performance:
+149.30%
1Y Performance:
+41.69%
1-Day Range:
$70.59
$71.09
1-Week Range:
$69.77
$71.09
52-Week Range:
$21.51
$72.05
Avidity Biosciences Inc Stock (RNA) Company Profile
Name
Avidity Biosciences Inc
Sector
Industry
Phone
858-401-7900
Address
3020 CALLAN ROAD, SAN DIEGO, CA
Compare RNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
70.80 | 10.67B | 10.73M | -455.74M | -502.70M | -3.5569 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Roth Capital | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Bernstein | Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Jun-11-25 | Initiated | Raymond James | Strong Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-20-24 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-24 | Initiated | Goldman | Buy |
| Aug-28-24 | Initiated | Barclays | Overweight |
| May-03-24 | Initiated | BofA Securities | Buy |
| Mar-14-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Strong Buy |
| Sep-07-21 | Initiated | Evercore ISI | Outperform |
| Jun-17-21 | Initiated | Needham | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | SVB Leerink | Outperform |
| Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Avidity Biosciences Inc Stock (RNA) Latest News
Will Avidity Biosciences Inc. stock attract more institutional investorsWeekly Stock Recap & Weekly High Return Forecasts - newser.com
Is Avidity Biosciences Inc. showing signs of accumulationJuly 2025 Setups & AI Enhanced Trading Signals - newser.com
Why Avidity Biosciences Inc. stock attracts global investorsMarket Risk Analysis & Real-Time Stock Entry Alerts - newser.com
What to expect from Avidity Biosciences Inc. in the next 30 daysJuly 2025 Final Week & Capital Protection Trading Alerts - newser.com
Heatmap analysis for Avidity Biosciences Inc. and competitorsJuly 2025 Analyst Calls & Low Risk High Reward Ideas - newser.com
How Avidity Biosciences Inc. stock compares to growth peers2025 Growth vs Value & Long-Term Growth Plans - newser.com
Applying Wyckoff theory to Avidity Biosciences Inc. stockJuly 2025 PreEarnings & Weekly High Momentum Picks - newser.com
How Avidity Biosciences Inc. stock benefits from strong dollarPortfolio Value Summary & AI Enhanced Market Trend Forecasts - newser.com
Visual analytics tools that track Avidity Biosciences Inc. performance2025 EndofYear Setup & Verified Momentum Stock Alerts - newser.com
US$12 Billion RNA Deal Triggers Sector Shakeup - streetwisereports.com
Should You Rethink Avidity Biosciences After 127% Rally on Trial Breakthroughs? - Yahoo Finance
Detecting support and resistance levels for Avidity Biosciences Inc.July 2025 EndofMonth & High Conviction Buy Zone Picks - newser.com
Price action breakdown for Avidity Biosciences Inc.July 2025 Decliners & Free Daily Entry Point Trade Alerts - newser.com
Using AI based signals to follow Avidity Biosciences Inc.July 2025 Analyst Calls & Growth Focused Investment Plans - newser.com
Why Avidity Biosciences Inc. stock is popular among millennialsJuly 2025 Setups & Verified Swing Trading Watchlists - newser.com
Risk adjusted return profile for Avidity Biosciences Inc. analyzedQuarterly Profit Review & Weekly Breakout Stock Alerts - newser.com
Can Avidity Biosciences Inc. stock deliver sustainable ROEJuly 2025 Recap & Free Fast Gain Swing Trade Alerts - newser.com
Short interest data insights for Avidity Biosciences Inc.Jobs Report & Expert Curated Trade Setups - newser.com
Avidity Biosciences stock reaches all-time high at 70.52 USD By Investing.com - Investing.com Nigeria
Will Avidity Biosciences Inc. stock deliver long term returns2025 Institutional Moves & Weekly Breakout Stock Alerts - newser.com
Chardan Capital Maintains Avidity Biosciences (RNA) Neutral Recommendation - Nasdaq
Avidity Biosciences stock reaches all-time high at 70.52 USD - Investing.com
Earnings visualization tools for Avidity Biosciences Inc.Quarterly Market Summary & AI Forecast for Swing Trade Picks - newser.com
Should Doubling of Net Losses in Q3 Require Action From Avidity Biosciences (RNA) Investors? - simplywall.st
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Beats Revenue Estimates - sharewise.com
Decoding Avidity Biosciences Inc (RNA): A Strategic SWOT Insight - GuruFocus
Avidity Biosciences Reports Increased Revenue Amid Losses - TipRanks
Avidity Biosciences Inc Stock (RNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avidity Biosciences Inc Stock (RNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hughes Steven George | Chief Medical Officer |
Oct 22 '25 |
Sale |
47.54 |
2,209 |
105,015 |
38,867 |
| McCarthy Teresa | Chief Human Resources Officer |
Oct 15 '25 |
Option Exercise |
22.34 |
20,000 |
446,800 |
117,130 |
| McCarthy Teresa | Chief Human Resources Officer |
Oct 15 '25 |
Sale |
50.15 |
20,000 |
1,003,058 |
97,130 |
| Mosbrooker Eric | Chief Commercial Officer |
Oct 03 '25 |
Option Exercise |
9.05 |
6,562 |
59,386 |
61,562 |
| Mosbrooker Eric | Chief Commercial Officer |
Oct 03 '25 |
Sale |
45.38 |
6,562 |
297,771 |
55,000 |
| Hughes Steven George | Chief Medical Officer |
Sep 22 '25 |
Option Exercise |
10.16 |
2,208 |
22,433 |
41,075 |
| Hughes Steven George | Chief Medical Officer |
Sep 22 '25 |
Sale |
40.58 |
2,208 |
89,601 |
38,867 |
| McCarthy Teresa | Chief Human Resources Officer |
Sep 15 '25 |
Option Exercise |
22.34 |
15,000 |
335,100 |
112,130 |
| McCarthy Teresa | Chief Human Resources Officer |
Sep 15 '25 |
Sale |
41.41 |
15,000 |
621,142 |
97,130 |
| Hughes Steven George | Chief Medical Officer |
Sep 15 '25 |
Option Exercise |
6.57 |
1,542 |
10,131 |
40,409 |
1.43%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):